CD274 and neoplasm: In the oncology setting, accumulating evidence indicates that the response to PD-1 or PD-L1 blockade is limited by both the abundance of tumor-reactive T cells whose function can be potentiated by treatment [45–47], and the involvement of multiple negative T-cell regulatory pathways [48,49].